Title:
UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/214053
Kind Code:
A1
Abstract:
A compound of formula (I) as a USP1 inhibitor or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, and the use thereof in the prevention or treatment of diseases associated with USP1.
Inventors:
ZHU WEI (CN)
ZOU HAO (CN)
MAI WANSUN (CN)
ZHU DONGXING (CN)
CHEN XIANG (CN)
WANG TAO (CN)
SUN TIANWEN (CN)
LI ZHENGTAO (CN)
ZOU HAO (CN)
MAI WANSUN (CN)
ZHU DONGXING (CN)
CHEN XIANG (CN)
WANG TAO (CN)
SUN TIANWEN (CN)
LI ZHENGTAO (CN)
Application Number:
PCT/CN2022/085703
Publication Date:
October 13, 2022
Filing Date:
April 08, 2022
Export Citation:
Assignee:
HAINAN SPARKLE THERAPEUTICS CO LTD (CN)
International Classes:
C07D417/14; A61K31/519; A61P35/00; C07D273/00; C07D291/08
Domestic Patent References:
| WO1996037481A1 | 1996-11-28 | |||
| WO2014086737A1 | 2014-06-12 |
Foreign References:
| CN109311868A | 2019-02-05 | |||
| CN111032662A | 2020-04-17 | |||
| CA2082668A1 | 1993-06-05 | |||
| CN106714800A | 2017-05-24 | |||
| US5620978A | 1997-04-15 | |||
| US5330989A | 1994-07-19 | |||
| CN202110403760A | 2021-04-09 | |||
| CN202110829701A | 2021-07-22 | |||
| CN202111166322A | 2021-09-30 | |||
| CN202111591747A | 2021-12-23 | |||
| CN202210242231A | 2022-03-11 |
Other References:
HUSSAIN, S.: "DUBs and cancer: The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors", CELL CYCLE, vol. 8, 2009, pages 1688 - 1697
Attorney, Agent or Firm:
INSIGHT INTELLECTUAL PROPERTY LIMITED (CN)
Download PDF: